Unknown PHASE1/PHASE2 INTERVENTIONAL NCT00431990

A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

Sponsor: Celgene Corporation

Interventions bortezomib depsipeptide dexamethasone

Updated 5 times since 2017 Last updated: Aug 11, 2011 Started: Nov 30, 2006 Primary completion: Dec 31, 2011 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00431990, this PHASE1/PHASE2 trial focuses on Multiple Myeloma and remains ongoing. Sponsored by Celgene Corporation, it has been updated 5 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1_PHASE2

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene Corporation
Janssen-Cilag Ltd.
Peter MacCallum Cancer Centre, Australia

Data source: Peter MacCallum Cancer Centre, Australia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Melbourne, Australia